Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | HCK | P08631 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.31 |
| ▸ | PRKDC | P78527 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30849917 | 0.89 | ALDH1A1 (0.35) | NLRP3KMT2A | |
| SCHEMBL20757631 | 0.83 | NLRP3 (0.34) | NLRP3 | |
| SCHEMBL20757246 | 0.82 | GAA (0.31) | — | |
| SCHEMBL23851046 | 0.81 | KMT2A (0.36) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL22824689 | 0.80 | KMT2A (0.31) | KMT2A | |
| SCHEMBL20757248 | 0.77 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL19869327 | 0.75 | PIK3CD (0.34) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL23063351 | 0.75 | RET (0.31) | — | |
| SCHEMBL20754810 | 0.74 | NLRP3 (0.34) | NLRP3PIK3CDABL1EGFRHCK | |
| Trifluoroacetic Acid SCHEMBL30849918 | 0.74 | CA12 (0.37) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-03-28 | — | — | US | disclosed |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-01-03 | — | — | US | disclosed |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-01-03 | — | — | US | disclosed |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| CN-111093773-A | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019034690-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034692-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399243-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885PIK3CD 3197/4885ABL1 3955/4885 |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, PYCARD | NLRP3 1/4885PIK3CD 3948/4885ABL1 4241/4885 |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, ABCC5 | NLRP3 1/4885PIK3CD 3313/4885ABL1 4200/4885 |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885PIK3CD 4365/4885ABL1 4345/4885 |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | NLRP3 1/4885PIK3CD 3948/4885ABL1 4241/4885 |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NLRP3 1/4885PIK3CD 4365/4885ABL1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.